Add
ITMN to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| ITMN > SEC Filings for ITMN > Form 8-K on 4-Nov-2009 | All Recent SEC Filings |
4-Nov-2009
Other Events, Financial Statements and Exhibits
In a press release issued on November 4, 2009, InterMune, Inc. announced that it had submitted an electronic New Drug Application, or NDA, with the U.S. Food and Drug Administration, or FDA, seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis, or IPF. Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.
(d) Exhibits.
Exhibit
No. Description
99.1 Press release dated November 4, 2009.
|
|